Top

 

References

  1. National Institute for Health and Clinical Excellence. Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Review of technology appraisal 98. Available at: www.nice.org.uk/TA98 [accessed August 2017].
  2. Diagnostic and Statistical Manual of mental disorders - Fifth Edition American Psychiatric Association, 2013.
  3. Scottish Intercollegiate Guidelines Network. Management of attention deficit and hyperkinetic disorders in children and young people: a national clinical guideline. Guideline 112; October 2009. Available at: http://www.sign.ac.uk/assets/sign112.pdf [accessed August 2017].
  4. Centers for disease control. Summary Health Statistics for US Children: National Interview Survey 2012 http://www.cdc.gov/nchs/data/series/sr_10/sr10_258.pdf Accessed August 2017.
  5. Gaub M, Carlson CL. Gender differences in ADHD: a meta-analysis and critical review. J Am Acad Child Adolesc Psychiatry 1997;36: 1036-45.
  6. Nutt DJ, et al. Evidence-based guidelines for management of attention-deficit/ hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2007;21(1): 10-41.
  7. Faraone SV, Perlis RH, Doyle AE, et al. Molecular genetics of attention-deficit/ hyperactivity disorder. Biol Psychiatry 2005; 57: 1313-1323.
  8. Castellanos FX, et al. Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/hyperactivity disorder. JAMA 2002; 288(14): 1740-8.
  9. Valera EM, et al. Meta-analysis of structural imaging findings in attention-deficit/ hyperactivity disorder. Biol Psychiatry 2007; 61(12): 1361-9.
  10. Spencer TJ, et al. Overview and neurobiology of ADHD. J Clinical Psych 2002; 63(S12): 3-9.
  11. Gillberg C, et al. Co-existing disorders in ADHD - implications for diagnosis and intervention. Eur Child Adolesc Psychiatry 2004; 13(Suppl 1):I80-92.
  12. Thompson AE, et al. Children with ADHD transferring to secondary school: Potential difficulties and solutions. Clinical Child Psychology and Psychiatry 2003;8(1): 91-103.
  13. All Party Parliamentary Group for Children (APPGC). `Every Child Matters` Green Paper. September 2003.
  14. Concerta® XL 18mg Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/6872 [accessed August 2017].
  15. Equasym® XL 10mg, 20mg or 30mg Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/medicine/15804  [accessed August 2017].
  16. Ritalin® Summary of Product Characteristics. Available at:  https://www.medicines.org.uk/emc/medicine/1316 [accessed August 2017].
  17. Amfexa® 10mg Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/medicine/32399 [accessed August 2017].
  18. Strattera® 10mg, 18mg, 25mg, 40mg, 60mg, 80mg and 100mg Summary of Product Characteristics. Available at:  https://www.medicines.org.uk/emc/medicine/14482 [accessed August 2017].
  19. Elvanse® 20mg, 30mg, 40mg 50mg, 60mg and 70mg Summary of Product Characteristics. Available at: http://www.medicines.org.uk/emc/medicine/27442 [accessed August 2017).
  20. Taylor E, et al. European clinical guidelines for hyperkinetic disorder - first upgrade. Eur Child Adolesc Psychiatry. 2004;13 Suppl 1;17-30
 

Top

ADHD-Mobile
Resource

Resources

Visit our resource centre for useful information and helpful activities for parents, teachers and teenagers living with ADHD.

Top

home_paralax_logo_320